Dr. Cardin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3601 The Vanderbilt Clinic
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-0605- Is this information wrong?
Summary
- Dr. Dana Cardin is an oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. She received her medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 14 years. She specializes in gastrointestinal cancer and pancreas cancer clinical trials.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009- Vanderbilt University Medical CenterResidency, Internal Medicine, 2004 - 2006
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2003 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2003
Certifications & Licensure
TN State Medical License 2005 - 2024
AL State Medical License 2020 - 2020- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2012 Jul 30
- Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Start of enrollment: 2013 May 01
- S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jan 06
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsFirst-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Maria Vieito, Rowan E Miller, Prashanth Har...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
- 4 citationsSafety and Efficacy of Avelumab in Small Bowel Adenocarcinoma.Dana B Cardin, Jill Gilbert, Jennifer G Whisenant, Gregory D Ayers, Florencia Jalikis, Kimberly B Dahlman, Jamye F O'Neal, Frank Revetta, Chanjuan Shi, Jordan Berlin> ;Clinical Colorectal Cancer. 2022 Sep 1
- 15 citationsTrends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.Michael LaPelusa, Chan Shen, Nina D Arhin, Dana Cardin, Marcus Tan, Kamran Idrees, Sunil Geevarghese, Jordan Berlin, Cathy Eng, Chakravarthy, B.> ;Cancers. 2022 Jan 7
- Join now to see all
Lectures
- Pilot study to test safety and efficacy of avelumab in small bowel adenocarcinoma (SBA).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Clinical Score Can Guide PRRT Therapy Decisions for Neuroendocrine TumorsJanuary 19th, 2022
Moonshot to Cure Cancer Initiative Hailed as Tipping PointJanuary 15th, 2016
Professional Memberships
- Member
Hospital Affiliations
Vanderbilt University Medical CenterNashville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
